ClinicalTrials.gg
TerminatedNCT00681863Updated May 23, 2014Results posted

Open-label Extension Study of Pramipexole in the Treatment of Children and Adolescents With Tourette Syndrome

A Phase 3 interventional study of pramipexole 0.125 mg BID and pramipexole 0.0625 mg QD in Tourette Syndrome, sponsored by Boehringer Ingelheim. Terminated at 14 sites in 2 countries. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2014-05-23.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

Why this study was terminated
Terminated for slow enrollment.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
45
Allocation
Non-randomized
Ages
6 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 139 studies in Tourette Syndrome with a site in United States — 20 open to participants now, 24 under way, 1 of them phase 3. Tourette Syndrome · United States.

Enrollment
43rd of 105
45 · median 33
Started
2008
with 3 others
Phase 3
10 of 139
none open now
Registered
31st of 139
by date

Among the 139 studies in Tourette Syndrome with a site in United States, this one is the 43rd largest by enrollment of the 105 interventional ones that give a count, is one of 4 that started in 2008, is one of 10 in phase 3, and was the 31st registered.

Tourette Syndrome

240 studies on the registry are indexed under Tourette Syndrome; 40 are open to participants now.

Browse Tourette Syndrome studies →

Open to participants now

20 of the 139 studies in Tourette Syndrome with a site in United States are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 33 Tourette Syndrome studies recruiting now, 9 (27%) set no upper age limit and 22 (67%) stop at 75 or younger; 20 take children under 18; 9 take healthy volunteers.

This study: 6 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 139 studies in Tourette Syndrome with a site in United States, or all of them as a file.
02

Study summary

The primary objective of this open-label, flexible dose study is to assess the safety and efficacy of pramipexole over a 24-week period in children and adolescents (age 6-17 years inclusive) diagnosed with Tourette Syndrome according to Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) criteria and who have completed either Study 248.641 (NCT 00681863) or 248.644 (NCT 00558467).

03

Conditions studied

  • Tourette Syndrome

Browse trials for

04

Who can participate

Ages eligible
6 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female patients aged 6-17 years at the time of enrollment into study 248.641 or 248.644 and who have completed study 248.641 or 248.644.
  2. Written provided by the patient's parent (or legal guardian) and assent provided by the patient consistent with International Conference on Harmonization (ICH) Good Clinical Practice (GCP) and local Institutional Review Board (IRB) requirements for children obtained prior to any study procedures being performed.
  3. Ability and willingness to comply with study treatment regimen and to complete study assessments.
  4. Females of having a negative serum pregnancy test at Visit 1.
  5. Females of childbearing potential must be using a medically accepted method throughout the study. Acceptable methods of birth control are limited to: Intra-Uterine Device (IUD), oral, implantable, injectable contraceptives or estrogen patch, double barrier method (spermicide + diaphragm), or abstinence at the discretion of the investigator

Exclusion criteria

Exclusion criteria

  1. Breastfeeding females.
  2. Development of any clinical condition in the preceding trial that in the investigator's opinion could be worsened by treatment with pramipexole.
  3. renal disease or serum creatinine out of this range: 0.3 1.0 mg/dL for patients aged 3-12 years and 0.5-1.4 mg/dL for patients aged 13+ years.
  4. Any of the following lab results at screening:

    (Hgb) below lower limit of normal (LLN) which is determined to be clinically significant Basal thyroid stimulating hormone (TSH), triiodothyronine (T3) or thyroxine (T4) clinically significant (at the investigator's discretion) out of normal range at screening (if not caused by substitution therapy according the investigator's opinion) Patients with any clinically significant abnormalities in laboratory parameters at screening at the investigator's discretion.

  5. Other clinically significant metabolic-endocrine, hematological, gastrointestinal disease, or pulmonary disease (such as severe asthma) in the opinion of the investigator that would preclude the patient from participating in this study.
  6. History or presence of schizophrenia or any psychotic disorder. History or presence of any psychiatric disorder requiring medical therapy with the exception for patients with a diagnosis of Tourette Syndrome (TS), Attention Deficit Hyperactivity Disorder (ADHD) or Obsessive Compulsive Disorder (OCD) who are not on therapy other than pramipexole.
  7. History or presence of clinical signs of epilepsy or seizures other than fever-related seizures in early childhood.
  8. History or presence of clinical signs of any malignant neoplasm including suspicious undiagnosed skin lesion (which may be melanoma), melanoma, or a history of melanoma.
  9. History of any other medical treatment for TS besides the study medication within 28 days prior to the baseline visit (14 days prior to baseline for guanfacine, 14 days prior to baseline for dopamine agonists, 14 days prior to baseline for L-Dopa, 35 days prior to baseline for fluoxetine).
  10. Patients receiving psychotherapy are excluded unless they started the treatment at least 3 months prior to starting the trial and no changes in treatment are planned for the duration of the study.
  11. Allergic response to pramipexole or the inactive ingredients in its tablet formulation.
  12. Non-compliance with study medication (defined as less than 80% or more than 120%) during the preceding Study 248.641 or 248.644.
  13. Concurrent participation in another clinical trial using any drug since completion of the preceding Study 248.641 or 248.644.
  14. Any other conditions, that in the opinion of the investigator, would interfere with the evaluation of the results or constitute a health hazard for the patient.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
45 participants (actual)

Study arms

  • Active comparator
    pramipexole 0.0625 mg BID (twice daily)

    all patients to receive one tablet of pramipexole 0.0625 mg BID for first 4 weeks (flexible dosing for all other arms)

    Drug: pramipexole 0.0625 mg BID

  • Active comparator
    pramipexole 0.0625 mg QD (once daily)

    patients to receive one tablet of pramipexole 0.0625 mg QD

    Drug: pramipexole 0.0625 mg QD

  • Active comparator
    pramipexole 0.125 mg BID

    patients to receive one tablet of pramipexole 0.125 mg BID

    Drug: pramipexole 0.125 mg BID

  • Active comparator
    pramipexole 0.125 mg TID (three times daily)

    patients to receive one tablet of pramipexole 0.125 mg TID

    Drug: pramipexole 0.125 mg TID

  • Active comparator
    pramipexole 0.25 mg BID

    patients to receive one tablet of pramipexole 0.25 mg BID

    Drug: pramipexole 0.25 mg BID

Interventions

06

What researchers measure

Primary outcomes

  1. Patients With Adverse Events Leading to Discontinuation of Trial Drug

    Number of patients with Adverse Events leading to discontinuation of trial drug

    Time frame: 24 Weeks

Secondary outcomes

  1. Mean Change From Baseline in Total Tic Score (TTS) of the Yale Global Tic Severity Scale

    Total Tic Score is the sum of ten individual ratings of the impairment due to tics. Each scale ranges from 0 (None/Absent) to 5 (Severe) and total score ranges from 0 to 50.

    Time frame: baseline and week 24

  2. Mean Change From Baseline in Total Score of the Yale Global Tic Severity Scale

    Total Score is a rating of the overall impairment due to motor and phonic tics. The scale ranges from 0 (None) to 50 (Severe).

    Time frame: baseline and Week 24 (end of treatment visit)

  3. Mean Change From Baseline in Total Tic Score (TTS) of the Yale Global Tic Severity Scale

    Total Tic Score is the sum of ten individual ratings of the impairment due to tics. Each scale ranges from 0 (None/Absent) to 5 (Severe) and total score ranges from 0 to 50.

    Time frame: baseline and Week 1

  4. Mean Change From Baseline in Total Tic Score (TTS) of the Yale Global Tic Severity Scale

    Total Tic Score is the sum of ten individual ratings of the impairment due to tics. Each scale ranges from 0 (None/Absent) to 5 (Severe) and total score ranges from 0 to 50.

    Time frame: baseline and Week 2

  5. Mean Change From Baseline in Total Tic Score (TTS) of the Yale Global Tic Severity Scale

    Total Tic Score is the sum of ten individual ratings of the impairment due to tics. Each scale ranges from 0 (None/Absent) to 5 (Severe) and total score ranges from 0 to 50.

    Time frame: baseline and Week 3

  6. Mean Change From Baseline in Total Tic Score (TTS) of the Yale Global Tic Severity Scale

    Total Tic Score is the sum of ten individual ratings of the impairment due to tics. Each scale ranges from 0 (None/Absent) to 5 (Severe) and total score ranges from 0 to 50.

    Time frame: baseline and week 4

  7. Mean Change From Baseline in Total Tic Score (TTS) of the Yale Global Tic Severity Scale

    Total Tic Score is the sum of ten individual ratings of the impairment due to tics. Each scale ranges from 0 (None/Absent) to 5 (Severe) and total score ranges from 0 to 50.

    Time frame: baseline and Week 8

  8. Mean Change From Baseline in Total Tic Score (TTS) of the Yale Global Tic Severity Scale

    Total Tic Score is the sum of ten individual ratings of the impairment due to tics. Each scale ranges from 0 (None/Absent) to 5 (Severe) and total score ranges from 0 to 50.

    Time frame: baseline and Week 12

  9. Mean Change From Baseline in Total Tic Score (TTS) of the Yale Global Tic Severity Scale

    Total Tic Score is the sum of ten individual ratings of the impairment due to tics. Each scale ranges from 0 (None/Absent) to 5 (Severe) and total score ranges from 0 to 50.

    Time frame: baseline and Week 16

  10. Mean Change From Baseline in Total Tic Score (TTS) of the Yale Global Tic Severity Scale

    Total Tic Score is the sum of ten individual ratings of the impairment due to tics. Each scale ranges from 0 (None/Absent) to 5 (Severe) and total score ranges from 0 to 50.

    Time frame: baseline and Week 20

  11. Mean Change From Baseline in Total Score of the Yale Global Tic Severity Scale

    Total Score is a rating of the overall impairment due to motor and phonic tics. The scale ranges from 0 (None) to 50 (Severe).

    Time frame: baseline and Week 1

  12. Mean Change From Baseline in Total Score of the Yale Global Tic Severity Scale

    Total Score is a rating of the overall impairment due to motor and phonic tics. The scale ranges from 0 (None) to 50 (Severe).

    Time frame: baseline and Week 2

  13. Mean Change From Baseline in Total Score of the Yale Global Tic Severity Scale

    Total Score is a rating of the overall impairment due to motor and phonic tics. The scale ranges from 0 (None) to 50 (Severe).

    Time frame: baseline and Week 3

  14. Mean Change From Baseline in Total Score of the Yale Global Tic Severity Scale

    Total Score is a rating of the overall impairment due to motor and phonic tics. The scale ranges from 0 (None) to 50 (Severe).

    Time frame: baseline and Week 4

  15. Mean Change From Baseline in Total Score of the Yale Global Tic Severity Scale

    Total Score is a rating of the overall impairment due to motor and phonic tics. The scale ranges from 0 (None) to 50 (Severe).

    Time frame: baseline and Week 8

  16. Mean Change From Baseline in Total Score of the Yale Global Tic Severity Scale

    Total Score is a rating of the overall impairment due to motor and phonic tics. The scale ranges from 0 (None) to 50 (Severe).

    Time frame: baseline and Week 12

  17. Mean Change From Baseline in Total Score of the Yale Global Tic Severity Scale

    Total Score is a rating of the overall impairment due to motor and phonic tics. The scale ranges from 0 (None) to 50 (Severe).

    Time frame: baseline and Week 16

  18. Mean Change From Baseline in Total Score of the Yale Global Tic Severity Scale

    Total Score is a rating of the overall impairment due to motor and phonic tics. The scale ranges from 0 (None) to 50 (Severe).

    Time frame: baseline and Week 20

  19. Mean Change From Baseline in Total Score of the Yale Global Tic Severity Scale

    Total Score is a rating of the overall impairment due to motor and phonic tics. The scale ranges from 0 (None) to 50 (Severe).

    Time frame: baseline and Week 24

  20. Clinical Global Impressions - Severity of Illness

    Overall improvement during the last week compared to baseline ranging from 1 (very much improved), 2 (much improved), to 7 (very much worse). Responder has 'very much' or 'much' improvement. Non responder has less improvement than 'much' improvement.

    Time frame: week 24

  21. Clinical Global Impressions - Severity of Illness, Categorized

    Assessment of the overall severity of illness on a scale ranging from 1 (not at all ill) to 7 (among the most extremely ill patients). Overall improvement during the last week compared to baseline ranging from 1 (very much improved), 2 (much improved), to 7 (very much worse). Responder has 'very much' or 'much' improvement. Non responder has less improvement than 'much' improvement.

    Time frame: week 24

  22. Clinical Global Impressions - Improvement

    Assessment of the overall improvement during the last week compared to the patient's condition at baseline on a scale ranging from 1 (very much improved) to 7 (very much worse).

    Time frame: week 1

  23. Clinical Global Impressions - Improvement

    Assessment of the overall improvement during the last week compared to the patient's condition at baseline on a scale ranging from 1 (very much improved) to 7 (very much worse).

    Time frame: week 2

  24. Clinical Global Impressions - Improvement

    Assessment of the overall improvement during the last week compared to the patient's condition at baseline on a scale ranging from 1 (very much improved) to 7 (very much worse).

    Time frame: week 3

  25. Clinical Global Impressions - Improvement

    Assessment of the overall improvement during the last week compared to the patient's condition at baseline on a scale ranging from 1 (very much improved) to 7 (very much worse).

    Time frame: week 4

  26. Clinical Global Impressions - Improvement

    Assessment of the overall improvement during the last week compared to the patient's condition at baseline on a scale ranging from 1 (very much improved) to 7 (very much worse).

    Time frame: week 8

  27. Clinical Global Impressions - Improvement

    Assessment of the overall improvement during the last week compared to the patient's condition at baseline on a scale ranging from 1 (very much improved) to 7 (very much worse).

    Time frame: week 12

  28. Clinical Global Impressions - Improvement

    Assessment of the overall improvement during the last week compared to the patient's condition at baseline on a scale ranging from 1 (very much improved) to 7 (very much worse).

    Time frame: week 16

  29. Clinical Global Impressions - Improvement

    Assessment of the overall improvement during the last week compared to the patient's condition at baseline on a scale ranging from 1 (very much improved) to 7 (very much worse).

    Time frame: week 20

  30. Clinical Global Impressions - Improvement

    Assessment of the overall improvement during the last week compared to the patient's condition at baseline on a scale ranging from 1 (very much improved) to 7 (very much worse).

    Time frame: week 24

  31. Patient Global Impression - Improvement

    Assessment of the change of the patient's overall condition during the last week compared to the patient's condition at baseline on a scale ranging from 1 (very much better) to 7 (very much worse). A responder is defined as having a response of very much (1) or much better (2).

    Time frame: week 1

  32. Patient Global Impression - Improvement

    Assessment of the change of the patient's overall condition during the last week compared to the patient's condition at baseline on a scale ranging from 1 (very much better) to 7 (very much worse). A responder is defined as having a response of very much (1) or much better (2).

    Time frame: week 2

  33. Patient Global Impression - Improvement

    Assessment of the change of the patient's overall condition during the last week compared to the patient's condition at baseline on a scale ranging from 1 (very much better) to 7 (very much worse). A responder is defined as having a response of very much (1) or much better (2).

    Time frame: week 3

  34. Patient Global Impression - Improvement

    Assessment of the change of the patient's overall condition during the last week compared to the patient's condition at baseline on a scale ranging from 1 (very much better) to 7 (very much worse). A responder is defined as having a response of very much (1) or much better (2).

    Time frame: week 4

  35. Patient Global Impression - Improvement

    Assessment of the change of the patient's overall condition during the last week compared to the patient's condition at baseline on a scale ranging from 1 (very much better) to 7 (very much worse). A responder is defined as having a response of very much (1) or much better (2).

    Time frame: week 8

  36. Patient Global Impression - Improvement

    Assessment of the change of the patient's overall condition during the last week compared to the patient's condition at baseline on a scale ranging from 1 (very much better) to 7 (very much worse). A responder is defined as having a response of very much (1) or much better (2).

    Time frame: week 12

  37. Patient Global Impression - Improvement

    Assessment of the change of the patient's overall condition during the last week compared to the patient's condition at baseline on a scale ranging from 1 (very much better) to 7 (very much worse). A responder is defined as having a response of very much (1) or much better (2).

    Time frame: week 16

  38. Patient Global Impression - Improvement

    Assessment of the change of the patient's overall condition during the last week compared to the patient's condition at baseline on a scale ranging from 1 (very much better) to 7 (very much worse). A responder is defined as having a response of very much (1) or much better (2).

    Time frame: week 20

  39. Patient Global Impression - Improvement

    Assessment of the change of the patient's overall condition during the last week compared to the patient's condition at baseline on a scale ranging from 1 (very much better) to 7 (very much worse). A responder is defined as having a response of very much (1) or much better (2).

    Time frame: week 24

  40. Frequency of Patients With Possible Clinically Significant Abnormalities for Laboratory Parameters

    Frequency of patients with possible clinically significant abnormalities for laboratory parameters (blood hematology and electrolyte assessments, serum chemistry, including follicle-stimulating hormone (FSH), luteinizing hormone (LH) and estradiol for pubertal female patients, prolactin in all patients, testosterone in pubertal male patients, urine analysis)

    Time frame: Baseline and 24 weeks

07

Results

Posted Dec 17, 2010
Limitations and caveats
The sponsor cancelled this trial prematurely. Thus, enrollment for 248.642 (NCT00681863) was significantly less than what was planned (120 planned vs. 45 entered). Therefore, the objectives of this study could not be fully assessed.

Participant flow

Participant flow — Overall Study
MilestonePramipexole
Started45
Completed22
Not completed23
Withdrew: Adverse event1
Withdrew: Lost to follow-up2
Withdrew: Lack of efficacy2
Withdrew: Other18

Outcome measures

SecondaryMean Change From Baseline in Total Tic Score (TTS) of the Yale Global Tic Severity Scale

Total Tic Score is the sum of ten individual ratings of the impairment due to tics. Each scale ranges from 0 (None/Absent) to 5 (Severe) and total score ranges from 0 to 50.

Time frame:
baseline and week 24
Reported as:
Mean · Score on a scale
Mean Change From Baseline in Total Tic Score (TTS) of the Yale Global Tic Severity Scale
Score on a scalePramipexole
Mean Change From Baseline in Total Tic Score (TTS) of the Yale Global Tic Severity Scale-9.8 ± 8.9
SecondaryMean Change From Baseline in Total Score of the Yale Global Tic Severity Scale

Total Score is a rating of the overall impairment due to motor and phonic tics. The scale ranges from 0 (None) to 50 (Severe).

Time frame:
baseline and Week 24 (end of treatment visit)
Reported as:
Mean · Score on a scale
Mean Change From Baseline in Total Score of the Yale Global Tic Severity Scale
Score on a scalePramipexole
Mean Change From Baseline in Total Score of the Yale Global Tic Severity Scale-22.0 ± 21.0
SecondaryMean Change From Baseline in Total Tic Score (TTS) of the Yale Global Tic Severity Scale

Total Tic Score is the sum of ten individual ratings of the impairment due to tics. Each scale ranges from 0 (None/Absent) to 5 (Severe) and total score ranges from 0 to 50.

Time frame:
baseline and Week 1
Reported as:
Mean · Score on a scale
Mean Change From Baseline in Total Tic Score (TTS) of the Yale Global Tic Severity Scale
Score on a scalePramipexole
Mean Change From Baseline in Total Tic Score (TTS) of the Yale Global Tic Severity Scale-7.2 ± 8.5
SecondaryMean Change From Baseline in Total Tic Score (TTS) of the Yale Global Tic Severity Scale

Total Tic Score is the sum of ten individual ratings of the impairment due to tics. Each scale ranges from 0 (None/Absent) to 5 (Severe) and total score ranges from 0 to 50.

Time frame:
baseline and Week 2
Reported as:
Mean · Score on a scale
Mean Change From Baseline in Total Tic Score (TTS) of the Yale Global Tic Severity Scale
Score on a scalePramipexole
Mean Change From Baseline in Total Tic Score (TTS) of the Yale Global Tic Severity Scale-8.3 ± 7.7
SecondaryMean Change From Baseline in Total Tic Score (TTS) of the Yale Global Tic Severity Scale

Total Tic Score is the sum of ten individual ratings of the impairment due to tics. Each scale ranges from 0 (None/Absent) to 5 (Severe) and total score ranges from 0 to 50.

Time frame:
baseline and Week 3
Reported as:
Mean · Score on a scale
Mean Change From Baseline in Total Tic Score (TTS) of the Yale Global Tic Severity Scale
Score on a scalePramipexole
Mean Change From Baseline in Total Tic Score (TTS) of the Yale Global Tic Severity Scale-8.6 ± 8.6
SecondaryMean Change From Baseline in Total Tic Score (TTS) of the Yale Global Tic Severity Scale

Total Tic Score is the sum of ten individual ratings of the impairment due to tics. Each scale ranges from 0 (None/Absent) to 5 (Severe) and total score ranges from 0 to 50.

Time frame:
baseline and week 4
Reported as:
Mean · Score on a scale
Mean Change From Baseline in Total Tic Score (TTS) of the Yale Global Tic Severity Scale
Score on a scalePramipexole
Mean Change From Baseline in Total Tic Score (TTS) of the Yale Global Tic Severity Scale-9.3 ± 9.7
SecondaryMean Change From Baseline in Total Tic Score (TTS) of the Yale Global Tic Severity Scale

Total Tic Score is the sum of ten individual ratings of the impairment due to tics. Each scale ranges from 0 (None/Absent) to 5 (Severe) and total score ranges from 0 to 50.

Time frame:
baseline and Week 8
Reported as:
Mean · Score on a scale
Mean Change From Baseline in Total Tic Score (TTS) of the Yale Global Tic Severity Scale
Score on a scalePramipexole
Mean Change From Baseline in Total Tic Score (TTS) of the Yale Global Tic Severity Scale-10.7 ± 9.4
SecondaryMean Change From Baseline in Total Tic Score (TTS) of the Yale Global Tic Severity Scale

Total Tic Score is the sum of ten individual ratings of the impairment due to tics. Each scale ranges from 0 (None/Absent) to 5 (Severe) and total score ranges from 0 to 50.

Time frame:
baseline and Week 12
Reported as:
Mean · Score on a scale
Mean Change From Baseline in Total Tic Score (TTS) of the Yale Global Tic Severity Scale
Score on a scalePramipexole
Mean Change From Baseline in Total Tic Score (TTS) of the Yale Global Tic Severity Scale-12.3 ± 9.0
SecondaryMean Change From Baseline in Total Tic Score (TTS) of the Yale Global Tic Severity Scale

Total Tic Score is the sum of ten individual ratings of the impairment due to tics. Each scale ranges from 0 (None/Absent) to 5 (Severe) and total score ranges from 0 to 50.

Time frame:
baseline and Week 16
Reported as:
Mean · Score on a scale
Mean Change From Baseline in Total Tic Score (TTS) of the Yale Global Tic Severity Scale
Score on a scalePramipexole
Mean Change From Baseline in Total Tic Score (TTS) of the Yale Global Tic Severity Scale-12.4 ± 9.3
SecondaryMean Change From Baseline in Total Tic Score (TTS) of the Yale Global Tic Severity Scale

Total Tic Score is the sum of ten individual ratings of the impairment due to tics. Each scale ranges from 0 (None/Absent) to 5 (Severe) and total score ranges from 0 to 50.

Time frame:
baseline and Week 20
Reported as:
Mean · Score on a scale
Mean Change From Baseline in Total Tic Score (TTS) of the Yale Global Tic Severity Scale
Score on a scalePramipexole
Mean Change From Baseline in Total Tic Score (TTS) of the Yale Global Tic Severity Scale-11.7 ± 11.3
SecondaryMean Change From Baseline in Total Tic Score (TTS) of the Yale Global Tic Severity Scale

Total Tic Score is the sum of ten individual ratings of the impairment due to tics. Each scale ranges from 0 (None/Absent) to 5 (Severe) and total score ranges from 0 to 50.

Time frame:
baseline and Week 24
Reported as:
Mean · Score on a scale
Mean Change From Baseline in Total Tic Score (TTS) of the Yale Global Tic Severity Scale
Score on a scalePramipexole
Mean Change From Baseline in Total Tic Score (TTS) of the Yale Global Tic Severity Scale-9.3 ± 10.4
SecondaryMean Change From Baseline in Total Score of the Yale Global Tic Severity Scale

Total Score is a rating of the overall impairment due to motor and phonic tics. The scale ranges from 0 (None) to 50 (Severe).

Time frame:
baseline and Week 1
Reported as:
Mean · Score on a scale
Mean Change From Baseline in Total Score of the Yale Global Tic Severity Scale
Score on a scalePramipexole
Mean Change From Baseline in Total Score of the Yale Global Tic Severity Scale-14.5 ± 18.2
SecondaryMean Change From Baseline in Total Score of the Yale Global Tic Severity Scale

Total Score is a rating of the overall impairment due to motor and phonic tics. The scale ranges from 0 (None) to 50 (Severe).

Time frame:
baseline and Week 2
Reported as:
Mean · Score on a scale
Mean Change From Baseline in Total Score of the Yale Global Tic Severity Scale
Score on a scalePramipexole
Mean Change From Baseline in Total Score of the Yale Global Tic Severity Scale-17.4 ± 17.6
SecondaryMean Change From Baseline in Total Score of the Yale Global Tic Severity Scale

Total Score is a rating of the overall impairment due to motor and phonic tics. The scale ranges from 0 (None) to 50 (Severe).

Time frame:
baseline and Week 3
Reported as:
Mean · Score on a scale
Mean Change From Baseline in Total Score of the Yale Global Tic Severity Scale
Score on a scalePramipexole
Mean Change From Baseline in Total Score of the Yale Global Tic Severity Scale-18.4 ± 19.8
SecondaryMean Change From Baseline in Total Score of the Yale Global Tic Severity Scale

Total Score is a rating of the overall impairment due to motor and phonic tics. The scale ranges from 0 (None) to 50 (Severe).

Time frame:
baseline and Week 4
Reported as:
Mean · Score on a scale
Mean Change From Baseline in Total Score of the Yale Global Tic Severity Scale
Score on a scalePramipexole
Mean Change From Baseline in Total Score of the Yale Global Tic Severity Scale-20.9 ± 21.5
SecondaryMean Change From Baseline in Total Score of the Yale Global Tic Severity Scale

Total Score is a rating of the overall impairment due to motor and phonic tics. The scale ranges from 0 (None) to 50 (Severe).

Time frame:
baseline and Week 8
Reported as:
Mean · Score on a scale
Mean Change From Baseline in Total Score of the Yale Global Tic Severity Scale
Score on a scalePramipexole
Mean Change From Baseline in Total Score of the Yale Global Tic Severity Scale-22.4 ± 21.9
SecondaryMean Change From Baseline in Total Score of the Yale Global Tic Severity Scale

Total Score is a rating of the overall impairment due to motor and phonic tics. The scale ranges from 0 (None) to 50 (Severe).

Time frame:
baseline and Week 12
Reported as:
Mean · Score on a scale
Mean Change From Baseline in Total Score of the Yale Global Tic Severity Scale
Score on a scalePramipexole
Mean Change From Baseline in Total Score of the Yale Global Tic Severity Scale-27.7 ± 20.9
SecondaryMean Change From Baseline in Total Score of the Yale Global Tic Severity Scale

Total Score is a rating of the overall impairment due to motor and phonic tics. The scale ranges from 0 (None) to 50 (Severe).

Time frame:
baseline and Week 16
Reported as:
Mean · Score on a scale
Mean Change From Baseline in Total Score of the Yale Global Tic Severity Scale
Score on a scalePramipexole
Mean Change From Baseline in Total Score of the Yale Global Tic Severity Scale-28.3 ± 20.2
SecondaryMean Change From Baseline in Total Score of the Yale Global Tic Severity Scale

Total Score is a rating of the overall impairment due to motor and phonic tics. The scale ranges from 0 (None) to 50 (Severe).

Time frame:
baseline and Week 20
Reported as:
Mean · Score on a scale
Mean Change From Baseline in Total Score of the Yale Global Tic Severity Scale
Score on a scalePramipexole
Mean Change From Baseline in Total Score of the Yale Global Tic Severity Scale-26.7 ± 24.9
SecondaryMean Change From Baseline in Total Score of the Yale Global Tic Severity Scale

Total Score is a rating of the overall impairment due to motor and phonic tics. The scale ranges from 0 (None) to 50 (Severe).

Time frame:
baseline and Week 24
Reported as:
Mean · Score on a scale
Mean Change From Baseline in Total Score of the Yale Global Tic Severity Scale
Score on a scalePramipexole
Mean Change From Baseline in Total Score of the Yale Global Tic Severity Scale-22.0 ± 23.6
SecondaryClinical Global Impressions - Severity of Illness

Overall improvement during the last week compared to baseline ranging from 1 (very much improved), 2 (much improved), to 7 (very much worse). Responder has 'very much' or 'much' improvement. Non responder has less improvement than 'much' improvement.

Time frame:
week 24
Reported as:
Mean · score on a scale
Clinical Global Impressions - Severity of Illness
score on a scalePramipexole
Clinical Global Impressions - Severity of Illness-1.1 ± 1.1
SecondaryClinical Global Impressions - Severity of Illness, Categorized

Assessment of the overall severity of illness on a scale ranging from 1 (not at all ill) to 7 (among the most extremely ill patients). Overall improvement during the last week compared to baseline ranging from 1 (very much improved), 2 (much improved), to 7 (very much worse). Responder has 'very much' or 'much' improvement. Non responder has less improvement than 'much' improvement.

Time frame:
week 24
Reported as:
Number · participants
Clinical Global Impressions - Severity of Illness, Categorized
participantsPramipexole
Improved (change score <= -2)11
Unchanged (change score of -1, 0, or +1)31
Worsened (change score >= +2)0
SecondaryClinical Global Impressions - Improvement

Assessment of the overall improvement during the last week compared to the patient's condition at baseline on a scale ranging from 1 (very much improved) to 7 (very much worse).

Time frame:
week 1

No measurements were reported for this outcome.

SecondaryClinical Global Impressions - Improvement

Assessment of the overall improvement during the last week compared to the patient's condition at baseline on a scale ranging from 1 (very much improved) to 7 (very much worse).

Time frame:
week 2

No measurements were reported for this outcome.

PrimaryPatients With Adverse Events Leading to Discontinuation of Trial Drug

Number of patients with Adverse Events leading to discontinuation of trial drug

Time frame:
24 Weeks
Reported as:
Number · participants
Patients With Adverse Events Leading to Discontinuation of Trial Drug
participantsPramipexole
Patients With Adverse Events Leading to Discontinuation of Trial Drug1
SecondaryClinical Global Impressions - Improvement

Assessment of the overall improvement during the last week compared to the patient's condition at baseline on a scale ranging from 1 (very much improved) to 7 (very much worse).

Time frame:
week 3

No measurements were reported for this outcome.

SecondaryClinical Global Impressions - Improvement

Assessment of the overall improvement during the last week compared to the patient's condition at baseline on a scale ranging from 1 (very much improved) to 7 (very much worse).

Time frame:
week 4

No measurements were reported for this outcome.

SecondaryClinical Global Impressions - Improvement

Assessment of the overall improvement during the last week compared to the patient's condition at baseline on a scale ranging from 1 (very much improved) to 7 (very much worse).

Time frame:
week 8

No measurements were reported for this outcome.

SecondaryClinical Global Impressions - Improvement

Assessment of the overall improvement during the last week compared to the patient's condition at baseline on a scale ranging from 1 (very much improved) to 7 (very much worse).

Time frame:
week 12

No measurements were reported for this outcome.

SecondaryClinical Global Impressions - Improvement

Assessment of the overall improvement during the last week compared to the patient's condition at baseline on a scale ranging from 1 (very much improved) to 7 (very much worse).

Time frame:
week 16

No measurements were reported for this outcome.

SecondaryClinical Global Impressions - Improvement

Assessment of the overall improvement during the last week compared to the patient's condition at baseline on a scale ranging from 1 (very much improved) to 7 (very much worse).

Time frame:
week 20

No measurements were reported for this outcome.

SecondaryClinical Global Impressions - Improvement

Assessment of the overall improvement during the last week compared to the patient's condition at baseline on a scale ranging from 1 (very much improved) to 7 (very much worse).

Time frame:
week 24
Reported as:
Number · participants
Clinical Global Impressions - Improvement
participantsPramipexole
Responder (Much improved or Very much improved)22
Not Responder23
SecondaryPatient Global Impression - Improvement

Assessment of the change of the patient's overall condition during the last week compared to the patient's condition at baseline on a scale ranging from 1 (very much better) to 7 (very much worse). A responder is defined as having a response of very much (1) or much better (2).

Time frame:
week 1

No measurements were reported for this outcome.

SecondaryPatient Global Impression - Improvement

Assessment of the change of the patient's overall condition during the last week compared to the patient's condition at baseline on a scale ranging from 1 (very much better) to 7 (very much worse). A responder is defined as having a response of very much (1) or much better (2).

Time frame:
week 2

No measurements were reported for this outcome.

SecondaryPatient Global Impression - Improvement

Assessment of the change of the patient's overall condition during the last week compared to the patient's condition at baseline on a scale ranging from 1 (very much better) to 7 (very much worse). A responder is defined as having a response of very much (1) or much better (2).

Time frame:
week 3

No measurements were reported for this outcome.

SecondaryPatient Global Impression - Improvement

Assessment of the change of the patient's overall condition during the last week compared to the patient's condition at baseline on a scale ranging from 1 (very much better) to 7 (very much worse). A responder is defined as having a response of very much (1) or much better (2).

Time frame:
week 4

No measurements were reported for this outcome.

SecondaryPatient Global Impression - Improvement

Assessment of the change of the patient's overall condition during the last week compared to the patient's condition at baseline on a scale ranging from 1 (very much better) to 7 (very much worse). A responder is defined as having a response of very much (1) or much better (2).

Time frame:
week 8

No measurements were reported for this outcome.

SecondaryPatient Global Impression - Improvement

Assessment of the change of the patient's overall condition during the last week compared to the patient's condition at baseline on a scale ranging from 1 (very much better) to 7 (very much worse). A responder is defined as having a response of very much (1) or much better (2).

Time frame:
week 12

No measurements were reported for this outcome.

SecondaryPatient Global Impression - Improvement

Assessment of the change of the patient's overall condition during the last week compared to the patient's condition at baseline on a scale ranging from 1 (very much better) to 7 (very much worse). A responder is defined as having a response of very much (1) or much better (2).

Time frame:
week 16

No measurements were reported for this outcome.

SecondaryPatient Global Impression - Improvement

Assessment of the change of the patient's overall condition during the last week compared to the patient's condition at baseline on a scale ranging from 1 (very much better) to 7 (very much worse). A responder is defined as having a response of very much (1) or much better (2).

Time frame:
week 20

No measurements were reported for this outcome.

SecondaryPatient Global Impression - Improvement

Assessment of the change of the patient's overall condition during the last week compared to the patient's condition at baseline on a scale ranging from 1 (very much better) to 7 (very much worse). A responder is defined as having a response of very much (1) or much better (2).

Time frame:
week 24
Reported as:
Number · participants
Patient Global Impression - Improvement
participantsPramipexole
Responder (Much better or Very much better)17
Not Responder28
SecondaryFrequency of Patients With Possible Clinically Significant Abnormalities for Laboratory Parameters

Frequency of patients with possible clinically significant abnormalities for laboratory parameters (blood hematology and electrolyte assessments, serum chemistry, including follicle-stimulating hormone (FSH), luteinizing hormone (LH) and estradiol for pubertal female patients, prolactin in all patients, testosterone in pubertal male patients, urine analysis)

Time frame:
Baseline and 24 weeks
Reported as:
Number · participants
Frequency of Patients With Possible Clinically Significant Abnormalities for Laboratory Parameters
participantsPramipexole
Haemoglobin - decrease2
Eosinophils - increase3
Phosphate - increase2
Alkaline phosphatase - increase1

Adverse events

Collected over up to 24 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pramipexole—1/45 (2.2%)35/45 (77.8%)
Most frequent serious events
Most frequent serious events
EventPramipexole
SyncopeNervous system disorders1/45
Most frequent other events
Showing 10 of 18
Most frequent other events
EventPramipexole
HeadacheNervous system disorders9/45
NauseaGastrointestinal disorders8/45
FatigueGeneral disorders6/45
NasopharyngitisInfections and infestations5/45
Abdominal pain upperGastrointestinal disorders4/45
VomitingGastrointestinal disorders4/45
PyrexiaGeneral disorders4/45
HypersensitivityImmune system disorders4/45
Upper respiratory tract infectionInfections and infestations4/45
Increased appetiteMetabolism and nutrition disorders4/45

Baseline characteristics

Treated Set (TS) included all patients who were entered, were dispensed study medication and were documented to have taken at least one dose of study medication.

Age, Continuous
Age, Continuous(Years)Pramipexole
Mean11.8 ± 2.8
Sex: Female, Male
Sex: Female, Male(Participants)Pramipexole
Female9
Male36
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Pramipexole
Hispanic or Latino6
Not Hispanic or Latino38
Unknown or Not Reported1
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Pramipexole
Black or African American5
White40
Duration of Tourettes Syndrome
Duration of Tourettes Syndrome(Participants)Pramipexole
More than 5 years10
Less than 1 year15
1 to 5 years20
Height
Height(centimeters)Pramipexole
Mean152.6 ± 19.4
Weight
Weight(kilograms)Pramipexole
Mean53.01 ± 21.58
Body mass index
Body mass index(kilograms/square meter)Pramipexole
Mean22.064 ± 5.930

5 further baseline measures are reported on the registry.

08

Study locations

14 sites
  • 248.642.0026 Boehringer Ingelheim Investigational Site
    Bradenton, Florida, United States
  • 248.642.0025 Boehringer Ingelheim Investigational Site
    Tampa, Florida, United States
  • 248.642.0006 Boehringer Ingelheim Investigational Site
    Columbus, Georgia, United States
  • 248.642.0005 Boehringer Ingelheim Investigational Site
    Cambridge, Massachusetts, United States
  • 248.642.0003 Boehringer Ingelheim Investigational Site
    Manhasset, New York, United States
  • 248.642.0009 Boehringer Ingelheim Investigational Site
    New York, New York, United States
  • 248.642.0018 Boehringer Ingelheim Investigational Site
    New York, New York, United States
  • 248.642.0013 Boehringer Ingelheim Investigational Site
    Orangeburg, New York, United States
  • 248.642.0029 Boehringer Ingelheim Investigational Site
    Oklahoma City, Oklahoma, United States
  • 248.642.0010 Boehringer Ingelheim Investigational Site
    Providence, Rhode Island, United States
  • 248.642.0030 Boehringer Ingelheim Investigational Site
    Memphis, Tennessee, United States
  • 248.642.0008 Boehringer Ingelheim Investigational Site
    Houston, Texas, United States
  • 248.642.0023 Boehringer Ingelheim Investigational Site
    Norfolk, Virginia, United States
  • 248.642.49004 Boehringer Ingelheim Investigational Site
    Ulm, Germany
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2008 and a primary completion of Oct 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2010, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2008
First posted
May 21, 2008
Start
May 2008
Primary completionActual
Oct 2009
Results first posted
Dec 17, 2010
Last update
May 23, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 23, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00681863
Responsible party
Sponsor
First posted
May 21, 2008
Start date
May 2008
Primary completion
Oct 2009
Results posted
Dec 17, 2010
Last update
May 23, 2014

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pramipexole

Start the discussion